Delivery Order SPE2DR25D9114-SPE2DR26FMDV4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,746.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $24,084.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 19, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a $17,746.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract, with an ultimate completion date of November 19, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $36,229.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is firm fixed-price with an ultimate completion date of October 16, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $15,860.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- The Defense Logistics Agency awarded a delivery order valued at $17,604.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on June 12, 2025, with an ultimate completion date of July 7, 2025, represents a discrete procurement action under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $15,814.25 by the Defense Logistics Agency on September 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries no set-aside designation and is scheduled for ultimate completion by October 16, 2025, with performance taking place at the awardee's Park Ridge facility. This delivery order represents...
- SPE2DR25D9114Indefinite Delivery Contract
- SPE2DR25D9114-SPE2DR26FMDV4Delivery Order
The Defense Logistics Agency awarded a $27,331.66 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The PPV-G GEN V represents a $30.3 billion acquisition strategy under which DMS Pharmaceutical Group was awarded a single-award indefinite delivery contract on November 13, 2025, with a $499,999,999 ceiling value and ultimate completion through December 31, 2036. This contract positions DMS Pharmaceutical Group as a critical pharmaceutical supplier authorized to provide a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The company's established performance on numerous delivery orders prior to the IDC award demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.3k | 11/4/25 |